Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer
The Prostate2002Vol. 51(4), pp. 268–275
Citations Over TimeTop 10% of 2002 papers
Abstract
Endoglin marks principally small, probably newly formed tumor vessels in zthe prostate, and is a promising prognostic marker for prostate cancer patients.
Related Papers
- → Endoglin (CD105): A Marker of Tumor Vasculature and Potential Target for Therapy(2008)351 cited
- → CD105 (Endoglin) as negative prognostic factor in AML(2019)27 cited
- Evaluation of Endoglin as an Angiogenesis Marker in Glioblastoma.(2015)
- Research progress in CD105 and its relation with tumors(2007)
- → Measurement of Microvessel Density Using CD105 (Endoglin) as a Marker in Prostatic Adenocarcinoma(2023)